Ocrelizumab Concentration Is a Good Predictor of SARS-CoV-2 Vaccination Response in Patients with Multiple Sclerosis › Research Explorer

DOI

https://doi.org/10.1002/ana.26534
Final published version

the T2B! immunity against SARS-CoV-2 study group

Original language	English
Pages (from-to)	103-108
Number of pages	6
Journal	Annals of neurology
Volume	93
Issue number	1
Early online date	2022
DOIs	https://doi.org/10.1002/ana.26534
Publication status	Published - Jan 2023

ID: 27499636